Sbd

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015 Mar;38(3):412-9

Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci USA. 2015 Jun 22

Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetol Metab Syndr. 2015 Feb 24;7:12

Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? Diabetes Care. 2014 May;37(5):1418-24

Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015 Feb;38(2):316-22

Lower serum 25 (OH) D concentrations in type 1 diabetes: A meta-analysis. Diabetes Res Clin Pract. 2015 Jun;108(3):e71-5

The role of glucagon on type 2 diabetes at a glance. Diabetol Metab Syndr. 2014 Aug 24;6(1):91

Refractory Hyperglycemia After Gastric Bypass Surgery: A Novel Subtype of Type 2 Diabetes? Diabetes Care. 2014Dec;37(12):e254-5

Sleep Duration and Risk of Type 2 Diabetes: A Meta-analysis of Prospective Studies. Diabetes Care. 2015 Mar;38(3):529-37

A Very Low-Carbohydrate, Low–Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial. Diabetes Care. 2014 Nov;37(11):2909-18

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131; Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21;390(10105):1833-1842

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2017 Dec;40(12):1756-1762

P093 - Vacinação contra gripe, pneumonia e febre amarela no DM - Renato Kfouri by SBD

Dr. Leão Zagury agradeceu em nome dos fundadores da SBD o empenho e atuação da Dra. Hermelinda by SBD

023 - Dr. Francisco Fonseca, Dr. Paulo Genestreti, Dra. Mônica Gabbay, Dr. Fernando Valente by SBD

1. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409 - Dr. Jued Tuma 2. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017 Feb;5(2):125-133 - Dr. Luciano Giacaglia 3. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 Aug 28 - Dr. Carlos Eduardo Barra Couri 4. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017 Aug 1;26(2):292-300 - Dr. Fernando Valente

1- Rastreamento da doença cardiovascular assintomática no paciente diabético (1´14´´-8´13´´) - Dr. Paulo Roberto Rizzo Genestreti 2- Consenso sobre o manejo do exercício no diabético tipo 1 (8´19´´-13´49´´) - Dra. Tatiana Valente 3- Efeitos cardiovasculares e metabólicos da metformina em indivíduos com diabetes tipo 1 - Estudo REMOVAL (13´55´´-19´11´´) - Dr. Arnaldo Moura Neto 4- Controle glicêmico precoce, doença cardiovascular e mortalidade no diabético tipo 2 (19´17´´-23´52´´) - Dr. Fernando Valente

1) Desfechos cardiovasculares dos inibidores da PCSK9 Dr. Rodrigo de Oliveira Moreira 2) Pancreatite aguda em DM2 tratados com inibidores da DPP4 Dr. Arnaldo Moura Neto 3) IMC na adolescência e morte cardiovascular na idade adulta Dra. Lívia Firmino Gonçalves 4) Doença hepática gordurosa não alcoólica no DM2 Dr. Fernando Valente

1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22 - Dr. José Francisco Kerr Saraiva 2. Dysregulation of glucose metabolism in preclinical type 1 diabetes. Pediatr Diabetes. 2016 Jul;17 Suppl 22:25-30 - Dra. Mônica Andrade Lima Gabbay 3. Whey protein: The "whey" forward for treatment of type 2 diabetes? World J Diabetes. 2015 Oct 25;6(14):1274-84 - Dra. Tatiana Valente 4. Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β-Blockers. Diabetes Care. 2016 Oct;39(10):1818-26 - Dr. Fernando Valente